273 related articles for article (PubMed ID: 32117719)
1. Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle.
Albahde MAH; Zhang P; Zhang Q; Li G; Wang W
Front Oncol; 2020; 10():49. PubMed ID: 32117719
[No Abstract] [Full Text] [Related]
2. TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
Jiang Y; Zhu C; Huang H; Huang G; Fu B; Xi X
BMC Cancer; 2023 Aug; 23(1):716. PubMed ID: 37528357
[TBL] [Abstract][Full Text] [Related]
3. Prognostic biomarker TUBA1C is correlated to immune cell infiltration in the tumor microenvironment of lung adenocarcinoma.
Bian T; Zheng M; Jiang D; Liu J; Sun H; Li X; Liu L; Zhang J; Liu Y
Cancer Cell Int; 2021 Mar; 21(1):144. PubMed ID: 33653340
[TBL] [Abstract][Full Text] [Related]
4. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
5. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
6. lncRNA differentiation antagonizing nonprotein coding RNA overexpression accelerates progression and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Chen L; Liu J; Tang T; Zhang YC; Liu MZ; Xu LY; Zhang J
Onco Targets Ther; 2018; 11():7955-7965. PubMed ID: 30519037
[TBL] [Abstract][Full Text] [Related]
7. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
8. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma.
Huang X; Zhao L; Jin Y; Wang Z; Li T; Xu H; Wang Q; Wang L
Front Oncol; 2022; 12():827051. PubMed ID: 35433491
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
10. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
[TBL] [Abstract][Full Text] [Related]
11. TUBA1C expression promotes proliferation by regulating the cell cycle and indicates poor prognosis in glioma.
Gui S; Chen P; Liu Y; Chen Q; Cheng T; Lv S; Zhou T; Song Z; Xiao J; He W; Yuan S; Cheng Z
Biochem Biophys Res Commun; 2021 Nov; 577():130-138. PubMed ID: 34517210
[TBL] [Abstract][Full Text] [Related]
12. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
[TBL] [Abstract][Full Text] [Related]
13. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
14. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation, apoptosis, and invasion by sponging miR-625 and miR-892b.
Hao L; Rong W; Bai L; Cui H; Zhang S; Li Y; Chen D; Meng X
J Cell Biochem; 2019 Mar; 120(3):3780-3789. PubMed ID: 30382592
[TBL] [Abstract][Full Text] [Related]
15. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
16. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
[TBL] [Abstract][Full Text] [Related]
18. KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
Li SS; Jiang WL; Xiao WQ; Li K; Zhang YF; Guo XY; Dai YQ; Zhao QY; Jiang MJ; Lu ZJ; Wan R
World J Gastrointest Oncol; 2019 Aug; 11(8):599-621. PubMed ID: 31435462
[TBL] [Abstract][Full Text] [Related]
19. Oligoadenylate synthetases-like is a prognostic biomarker and therapeutic target in pancreatic ductal adenocarcinoma.
Chen S; Sun Z; Zhao W; Meng M; Guo W; Wu D; Shu Q; Chai J; Wang L
Ann Transl Med; 2022 Feb; 10(3):138. PubMed ID: 35284540
[TBL] [Abstract][Full Text] [Related]
20. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]